100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes

Pearson, James A. ORCID: https://orcid.org/0000-0002-2867-2269, McKinney, Eoin F. and Walker, Lucy S. K. 2022. 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. Immunotherapy Advances 10.1093/immadv/ltab024

PDF - Published Version Available under License Creative Commons Attribution. Download (3MB)

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here, we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited
ISSN:	2732-4303
Funders:	MRC, JDRF, Wellcome Trust
Date of First Compliant Deposit:	21 January 2022
Date of Acceptance:	20 November 2021
Last Modified:	12 May 2023 23:14
URI:	https://orca.cardiff.ac.uk/id/eprint/146829

Actions (repository staff only)

Edit Item